Medicines Co
Change company Symbol lookup
Select an option...
MDCO Medicines Co
MBI MBIA Inc
VXX iPath S&P 500 VIX Short-Term Futures, ETN
ASHSX AllianzGI Short Duration High Income Fund Class R6
PRSS CafePress Inc
PINC Premier Inc
MTOR Meritor Inc
INFCX ALPS
ETN Eaton Corporation PLC
VGSH Vanguard Short-Term Government Bond Index Fund ETF Shares
Go

Health Care : Pharmaceuticals | Small Cap BlendCompany profile

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin). It also has a pipeline of products in development, including Carbavance, inclisiran and MDCO-700. Carbavance is used for the treatment of hospitalized patients with gram-negative bacterial infections. Inclisiran is used for the treatment of hypercholesterolemia. MDCO-700 includes sedative-hypnotic, which is used to induce and maintain sedation for procedural care and general anesthesia for surgical care. In addition to these products and products in development, it has a portfolio of generic drugs.

Closing Price
$33.60
Day's Change
-0.06 (-0.18%)
Bid
--
Ask
--
B/A Size
--
Day's High
33.87
Day's Low
33.32
Volume
(Light)
Volume:
516,672

10-day average volume:
888,951
516,672

Company Profile

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin). It also has a pipeline of products in development, including Carbavance, inclisiran and MDCO-700. Carbavance is used for the treatment of hospitalized patients with gram-negative bacterial infections. Inclisiran is used for the treatment of hypercholesterolemia. MDCO-700 includes sedative-hypnotic, which is used to induce and maintain sedation for procedural care and general anesthesia for surgical care. In addition to these products and products in development, it has a portfolio of generic drugs.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
95.90x
Price/Book (MRQ)
116.89x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

August 2018
Current Month
17.5M
Previous Month
17.9M
Percent of Float
24.97%
Days to Cover
29.4081 Days

Share Information

MDCO is in a share class of common stock
Float
70.3M
Shares Outstanding
73.8M
Institutions Holding Shares
248
128.33%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Clive A. MeanwellCEO
  • Christopher VisioliCFO
  • Christopher T. CoxExec.VP
  • Stephen M. RodinCounsel
  • Paris PanayiotopoulosDir.

Address

Insider Trading

During the most recent quarter, 185K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by , Copyright © 2018. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.